Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
2PHARMA from Gent, company number BE0886662746, closed financial year 2025 with a result of € 120,628 after tax. For that financial year 2PHARMA recorded a gross margin of € 296,218 and equity of € 779,467. Compared with financial year 2024, the result moved from € 83,988 to € 120,628. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.
€ 779,467
▲ 18% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 120,628
▲ 44% vs 2024
Profit after tax over the fiscal year.
€ 756
▼ 77% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 404,467.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 275,989
▲ 15% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 67,325
▲ 266% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 1,438,296 | € 1,642,236 | € 1,252,796 | - | |
| Gross margin | - | € 33,005 | € -251 | € 296,218 | ▲ € 296,469 |
| Profit after taxes | € 22,179 | € 38,055 | € 83,988 | € 120,628 | ▲ 44% |
| Equity | € 536,795 | € 574,849 | € 658,838 | € 779,467 | ▲ 18% |
| Total debts | € 546,412 | € 284,896 | € 264,421 | € 343,314 | ▲ 30% |
| Cash | € 94,166 | € 3,363 | € 3,310 | € 756 | ▼ 77% |
| Retained profit | € 161,795 | € 199,849 | € 283,838 | € 404,467 | ▲ 42% |
| Balance sheet total | € 1,083,207 | € 859,745 | € 923,259 | € 1,122,781 | ▲ 22% |
Key figures of 2PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to 2PHARMA?
What happened at 2PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Aquitania BV stepped down as director. NBB
- MD Consult BV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 120,628 (▲ 44% vs 2024). Source: NBB ↗
- Aquitania BV became a director. NBB
- MD Consult BV became a director. NBB
- SDV Consult BV stepped down as director. NBB
- SDV Consult BV became a director. NBB
- New establishment in Gent. KBO
In short
From € 22,179 profit in 2022 to € 120,628 profit in 2025.
Paid € 56,766 in corporate taxes since 2022.
Best year ever: 2025, with € 120,628 profit.
A new publication or filing at 2PHARMA? We notify you, reason included.
Follow 2PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of 2PHARMA HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
2PHARMAThe shares are held by 2PHARMA HOLDING (100%).
Directors
According to the 2025 annual accounts
since 2019 · until 2025
Director · represented by Anja Imschoot
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium, DGPharma, Labophar, 2PHARMA HOLDING, MD Pharma, GLOBIFER INTL +1 more
since 2026 · until 2032
Managing director · represented by Mario Debel
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, 2PHARMA HOLDING, MD Pharma, Azur Medical, AUGMENTED ANATOMY, GLOBIFER INTL, CREDOPHAR
since 2026 · until 2032
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
DGPharma same network
€ 94,120 gross margin · 2024
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0886.662.746
- VAT number
- BE 0886.662.746
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- 2PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 January 2007
- Peppol
- Active · Active since 26 Aug 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen